Bintai Kinden partner to develop China's li-Key Covid-19 vaccine
2 minutes
KUALA LUMPUR: Bintai Kinden Corp bhd's partner Generex Biotechnology Corporation has entered a framework agreement with Chinese agencies to develop and commercialise a coronavirus vaccine in China.
It said in a statement issued today that Generex had entered the agreement with China Center for Disease Control and Prevention, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd.
Under the terms of the agreement, Generex will receive upfront development fees and back-end licensing payments to conduct the research and development and fully fund the commercial approval of the Ii-Key-CoV-2 vaccine.
This will include laboratory work, manufacturing, regulatory filings and the clinical development programme for regulatory approval of the vaccine in China.
“The involvement of China’s state-owned fund and cooperation at the highest government level through the China CDC increases the likelihood of success of the vaccine commercialization efforts”, said Bintai Kinden managing director Ong Choon Lui.
Bintai Kinden's subsdiary Bintai Healthcare Sdn Bhd has a distribution and licensing agreement with Generex for its Covid-19 vaccine in malaysia.
Under the agreement, Bintai Healthcare was granted the exclusive rights to distribute, sell and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, Philippines, Singapore, Thailand and Vietnam.
It will also have the right of first refusal to commercially exploit the vaccine within New Zealand, Australia and the global halal market, it said.
https://www.thestar.com.my/business/business-news/2020/11/05/bintai-kinden-partner-to-develop-china039s-li-key-covid-19-vaccine
